Hospital Universitario Ramon y Cajal   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Madrid Spain (1977)

Organization Overview

First Clinical Trial
2009
NCT01377792
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Adelaida Lamas Ferreiro | Hospital Universitario Ramon y Cajal | Hospital Univ. Ramón y Cajal | Jose Luis Vazquez Martinez | President of CEIC Hospital Ramon y Cajal | Vivencio Barrios

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Acute Kidney Injury (Phase 2)

Aspergillosis (Phase 1)

Asthma (Phase 4)

Colorectal Neoplasms (Phase 3)

Communicable Diseases (Phase 4)

Cystic Fibrosis (Phase 4)

Fibrosis (Phase 4)

Heart Failure (Phase 2)

HIV Infections (Phase 4)

Infections (Phase 4)

Inflammation (Phase 4)

Invasive Pulmonary Aspergillosis (Phase 1)

Kidney Failure, Chronic (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Pulmonary Aspergillosis (Phase 1)

Renal Insufficiency (Phase 2)

Shock (Phase 4)

Shock, Cardiogenic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 30